Lsv Asset Management Vanda Pharmaceuticals Inc. Transaction History

Lsv Asset Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 03, 2023	SELL	$4.28 - $6.57 $65,620 - $100,731	-15,332 Reduced 69.38%	6,768 $29,000
Q2 2023 Aug 02, 2023	SELL	$5.9 - $6.95 $301,490 - $355,145	-51,100 Reduced 69.81%	22,100 $146,000
Q3 2022 Nov 07, 2022	SELL	$9.44 - $11.76 $524,864 - $653,856	-55,600 Reduced 43.17%	73,200 $723,000
Q2 2022 Aug 10, 2022	SELL	$9.31 - $11.84 $19.9 Million - $25.3 Million	-2,136,437 Reduced 94.31%	128,800 $1.4 Million
Q1 2022 May 12, 2022	BUY	$10.84 - $16.55 $51,544 - $78,695	4,755 Added 0.21%	2,265,237 $25.6 Million
Q4 2021 Jan 28, 2022	BUY	$15.69 - $21.14 $2.06 Million - $2.78 Million	131,385 Added 6.17%	2,260,482 $35.5 Million
Q3 2021 Nov 04, 2021	BUY	$15.35 - $21.27 $4.28 Million - $5.94 Million	279,049 Added 15.08%	2,129,097 $36.5 Million
Q2 2021 Aug 04, 2021	BUY	$15.71 - $21.51 $8.34 Million - $11.4 Million	531,066 Added 40.26%	1,850,048 $39.8 Million
Q1 2021 Apr 30, 2021	BUY	$13.42 - $20.28 $12.6 Million - $19 Million	937,565 Added 245.81%	1,318,982 $19.8 Million
Q4 2020 Feb 08, 2021	BUY	$9.77 - $13.81 $3.73 Million - $5.27 Million	381,417 New	381,417 $5.01 Million

156

44.7M

167K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $271M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

Stay updated on Lsv Asset Management with notifications on news.